logo
Dr. Zavier Ash Launches New Website to Expand Access to Functional Medicine Services

Dr. Zavier Ash Launches New Website to Expand Access to Functional Medicine Services

Globe and Mail20-05-2025

The new site highlights Dr. Ash's personal approach to holistic healthcare, offering resources for patients seeking alternatives to traditional medicine
Dr. Zavier Ash, a respected physician with over 25 years of experience in both traditional and holistic medicine, is proud to announce the launch of his brand new personal website: https://www.drzavierashgeorgia.com/.
The website is designed to serve as a central .hub for patients and visitors looking to learn more about Dr. Ash's unique approach to functional medicine. Visitors can now access detailed information about his two independent practices: AshCare Functional Medicine, LLC and 7Days Of Weight & Wellness, LLC, both based in Tucker, Georgia.
Dr. Ash has built his career on listening closely to his patients and treating the root causes of illness rather than just the symptoms. The website reflects that philosophy with easy-to-navigate sections that outline services, qualifications, and practical information for new and returning patients.
'My goal was to create a place online where people could truly understand what I do and how I can help,' said Dr. Ash. 'The way we treat health is changing, and I wanted my website to reflect that shift.'
One key feature of the site is information on Dr. Ash's certifications. He is listed on the FMCSA National Registry of Certified Medical Examiners, allowing him to perform DOT physical exams. He is also a USCIS Civil Surgeon serving Dekalb and Gwinnett counties, authorised to conduct immigration physicals.
The site also offers background on Dr. Ash's academic and professional journey, from his early education at Morehouse College to his medical degree from Meharry Medical College, and residencies in OBGYN and family medicine at East Carolina University.
By launching this personal website, Dr. Ash aims to make his services more accessible while also educating the public about the value of functional and integrative healthcare.
About Dr. Zavier Ash
Dr. Zavier Ash is a physician based in Tucker, GA, with more than 25 years of experience in traditional and functional medicine. He is the founder of AshCare Functional Medicine, LLC and 7Days Of Weight & Wellness, LLC. He is FMCSA certified to conduct DOT physicals and is a USCIS Civil Surgeon. Dr. Ash focuses on treating the whole person using a blend of modern medical science and natural remedies.
To read more, visit the website here:
Media Contact
Contact Person: Dr. Zavier Ash
Email: Send Email
City: Tucker
State: GA
Country: United States
Website: https://www.drzavierashgeorgia.com/

Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

PD-L1 Inhibitors Market Insight, Epidemiology, and Market Forecast – 2034
PD-L1 Inhibitors Market Insight, Epidemiology, and Market Forecast – 2034

Globe and Mail

time2 hours ago

  • Globe and Mail

PD-L1 Inhibitors Market Insight, Epidemiology, and Market Forecast – 2034

PD-L1 inhibitors have become a vital part of modern cancer therapy by blocking the PD-1/PD-L1 pathway, which tumors use to evade immune detection. By restoring T-cell function, these therapies boost the body's ability to fight cancer. They have shown significant clinical benefit, including durable responses and improved survival, in several cancers such as NSCLC, TNBC, renal cell carcinoma, urothelial carcinoma, and head and neck squamous cell carcinoma. DelveInsight's ' PD-L1 Inhibitors Market Report ' provides an in-depth analysis of the current and future market landscape for PD-L1 inhibitors across the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), Japan, and other key geographies. The report offers comprehensive epidemiological insights, treatment algorithms, evolving biomarker trends, and the competitive environment surrounding PD-L1-targeting therapies. Currently marketed PD-L1 inhibitors, including TECENTRIQ, IMFINZI, and BAVENCIO, have expanded their indications through successful regulatory approvals. These agents are widely used as monotherapy or in combination with chemotherapy, anti-VEGF agents, or other immune checkpoint inhibitors, depending on cancer type and biomarker expression. The market is witnessing dynamic growth driven by increasing PD-L1 biomarker testing, expanded indications, strategic collaborations, and next-generation immuno-oncology research. The development pipeline includes novel PD-L1 inhibitors, bispecific antibodies, and combination regimens aimed at overcoming resistance and improving patient outcomes. Companies such as EQRx, CStone Pharmaceuticals, Pfizer, Novartis, and others are leading the field with continuous investment in clinical trials and label expansions. However, challenges persist, including the identification of optimal biomarkers for patient selection, immune-related adverse events, resistance mechanisms, and cost-effectiveness concerns. Despite these hurdles, the PD-L1 inhibitor market is expected to grow substantially through 2034, supported by ongoing innovations, broader clinical acceptance, and rising global cancer burden. This report serves as a vital resource for pharmaceutical companies, investors, clinical researchers, and oncologists looking to navigate the evolving PD-L1 inhibitor landscape, assess market opportunities, and drive strategic decision-making. Some of the Key Facts of the PD-L1 Inhibitors Market Report: • In 2023, the PD-L1 inhibitors market size in the 7MM was approximately USD 36 billion, with the United States contributing the largest share. • Key indications in the U.S. (2023 incident cases): • KEYTRUDA and OPDIVO, the leading PD-L1 inhibitors, are expected to lose patent exclusivity in the U.S. by 2028, potentially impacting market dynamics. • The loss of exclusivity may lead to a market decline, as biosimilars emerge and new entrants may struggle to match the current dominance of KEYTRUDA and OPDIVO, even with approvals in multiple indications. • Clinical trial activity has surged, over 4,400 trials registered, with more than 3,600 ongoing. • Around 90% of new trials since 2020 are exploring PD-L1 inhibitors in combination regimens, highlighting a strong shift towards combination strategies. • In April 2025, Gilead Sciences reported positive results from the Phase III ASCENT-04/KEYNOTE-D19 study, showing that the combination of TRODELVY (sacituzumab govitecan-hziy) and KEYTRUDA (pembrolizumab) significantly improved progression-free survival in patients with metastatic triple-negative breast cancer (mTNBC) whose tumors express PD-L1 (CPS ≥ 10), compared to chemotherapy and KEYTRUDA alone. • In March 2025, the FDA granted traditional approval for frontline pembrolizumab (Keytruda) in combination with trastuzumab and chemotherapy (fluoropyrimidine- and platinum-based) for adults with locally advanced, unresectable, or metastatic HER2-positive gastric or gastroesophageal junction (GEJ) adenocarcinoma whose tumors express PD-L1 with a combined positive score (CPS) of at least 1 (CPS ≥1). • In March 2025, the FDA granted traditional approval to pembrolizumab (Keytruda, Merck) with trastuzumab, fluoropyrimidine- and platinum-based chemotherapy for the first-line treatment of adults with locally advanced unresectable or metastatic HER2-positive gastric or gastroesophageal junction (GEJ) adenocarcinoma whose tumors express PD-L1 (CPS ≥1). • In February 2025, the FDA granted Regenerative Medicine Advanced Therapy (RMAT) status to nogapendekin alfa (Anktiva) and CAR-NK (PD-L1 t-haNK) for their potential to reverse lymphopenia in patients undergoing chemotherapy/radiotherapy and to treat metastatic pancreatic cancer. • In February 2025, Beijing Biostar Pharmaceuticals announced that its Utidelone Capsules, in combination with capecitabine and oxaliplatin, received FDA approval for a Phase II/III registration clinical study (BG02-2404). This Combination Therapy is for first-line treatment of PD-L1-negative, locally advanced or metastatic gastric or gastroesophageal junction adenocarcinoma. • In January 2025, the FDA approved tislelizumab, in combination with platinum- and fluoropyrimidine-based chemotherapy, for the first-line treatment of patients with unresectable or metastatic, HER2-negative gastric or gastroesophageal junction (GEJ) adenocarcinoma whose tumors express PD-L1 (≥1). • Leading companies in the PD-L1 Inhibitors market include EQRx, CStone Pharmaceuticals, Pfizer, Novartis, Arcus Biosciences, Agenus, TRACON Pharmaceuticals, Shanghai Henlius Biotech, Incyte Corporation, and others. • Emerging acute PD-L1 inhibitor drugs include Sugemalimab (CS1001), Sasanlimab, Spartalizumab, Zimberelimab, Balstilimab, Envafolimab, HLX10, INCB099280, and others. • PD-L1 inhibitors are reshaping cancer care, fueling demand for more targeted and durable treatment options across multiple tumor types with growing clinical adoption and expanding indications. To know in detail about the PD-L1 Inhibitors market outlook, drug uptake, treatment scenario, and epidemiology trends, click here: PD-L1 Inhibitors Overview Programmed death-ligand 1 (PD-L1) inhibitors are a class of immune checkpoint inhibitors that have revolutionized cancer immunotherapy by enhancing the body's natural ability to fight tumors. PD-L1 is a protein expressed on tumor cells and tumor-infiltrating immune cells that binds to the PD-1 receptor on T-cells, effectively turning off the immune response. By blocking this interaction, PD-L1 inhibitors restore T-cell activity, allowing the immune system to recognize and destroy cancer cells more effectively. PD-L1 inhibitors are currently approved for a variety of malignancies, including non-small cell lung cancer (NSCLC), urothelial carcinoma, triple-negative breast cancer (TNBC), hepatocellular carcinoma, and others. Some of the key PD-L1 inhibitors include atezolizumab (TECENTRIQ), durvalumab (IMFINZI), and avelumab (BAVENCIO). These therapies are often used either as monotherapy or in combination with chemotherapy, targeted therapy, or other immunotherapies. Ongoing research continues to expand its applications across tumor types and disease stages, and the development of predictive biomarkers aims to refine patient selection for optimal treatment outcomes. With multiple agents in clinical and preclinical development, PD-L1 inhibitors remain a cornerstone of immuno-oncology, offering the potential for improved survival, long-term remission, and better quality of life for patients with advanced cancers. Get a free sample of the PD-L1 Inhibitors market report with key insights and emerging therapies here: PD-L1 Inhibitors Epidemiology The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2020 to 2034. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends. Download the report to understand which factors are driving PD-L1 Inhibitors epidemiology trends @ PD-L1 Inhibitors Epidemiology Forecast PD-L1 Inhibitor Drugs Uptake and Pipeline Development Activities The PD-L1 Inhibitors drugs uptake section examines the rate at which newly launched or upcoming potential drugs are being adopted in the PD-L1 Inhibitors market during the study period. This analysis covers drug uptake, patient adoption of therapies, and the sales performance of each drug. Additionally, the therapeutics assessment section highlights the drugs with the most rapid uptake, shedding light on the factors driving their widespread use. It also provides a comparative analysis of these drugs based on their market share. The report further delves into the PD-L1 Inhibitors pipeline development activities, offering key insights into various therapeutic candidates in different stages of development and the major companies behind these innovations. It also covers recent collaborations, acquisitions, mergers, licensing agreements, patent details, and other critical information related to emerging therapies. PD-L1 Inhibitors Market Outlook The PD-L1 inhibitors market is poised for continued growth, with PD-1/PD-L1 inhibitors expected to lead oncology drug sales in the coming years. These immuno-oncology agents have revolutionized cancer care across various tumor types and stages, from metastatic to early disease, thanks to their adaptability and durable clinical benefits. Widely adopted as monotherapy or in combination with tyrosine kinase inhibitors, chemotherapy, or other immunotherapies, PD-L1 inhibitors offer prolonged tumor responses and enhanced survival outcomes while maintaining a favorable safety profile that supports their use in broad combination regimens. While immune checkpoint inhibitors have transformed the cancer treatment landscape, efforts to target pathways beyond PD-1/PD-L1—such as TIGIT, TIM-3, and LAG-3—have met with limited success, though some agents continue development. Innovative approaches like Eftilagimod alpha (Efti), a unique MHC Class II agonist, are also gaining attention for combination strategies. In an increasingly crowded PD-L1 market, innovation and differentiation are critical. Companies must target new indications, address current treatment gaps, or become first-in-class to maintain a competitive advantage. Emerging PD-L1 inhibitors such as spartalizumab (Novartis), sasanlimab (Pfizer), zimberelimab (Arcus Biosciences), sugemalimab (EQRx/CStone), HLX10 (Henlius), and balstilimab (Agenus) are currently in development. Among the 7MM, the United States remains the largest market for PD-L1 inhibitors, generating nearly USD 26 billion in 2023, with further expansion anticipated through 2034. PD-L1 Inhibitors Market Strengths • PD-L1 inhibitors are approved for a wide range of tumor types, including non-small cell lung cancer, bladder cancer, melanoma, and more. Their use as monotherapy or in combination regimens gives them a significant advantage in oncology treatment strategies. • With numerous promising candidates in clinical development, such as spartalizumab, sasanlimab, and sugemalimab, the pipeline remains robust. Continued R&D investment ensures ongoing evolution and expansion into new indications and combinations. PD-L1 Inhibitors Market Weaknesses • The PD-L1 inhibitors landscape is crowded with multiple approved agents and late-stage candidates, making it difficult for new entrants to differentiate and capture market share without clear clinical or safety advantages. • Attempts to extend the checkpoint blockade approach beyond PD-1/PD-L1 (e.g., targeting TIGIT, TIM-3) have faced clinical setbacks. This limits expansion opportunities and raises concerns about over-reliance on the PD-1/PD-L1 axis. Scope of the PD-L1 Inhibitors Market Report • Study Period: 2020–2034 • Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan] • Key PD-L1 Inhibitors Companies: EQRx, CStone Pharmaceuticals, Pfizer, Novartis, Arcus Biosciences, Agenus, TRACON Pharmaceuticals, Shanghai Henlius Biotech, Incyte Corporation, and others. • Key PD-L1 Inhibitors Therapies: Sugemalimab (CS1001), Sasanlimab, Spartalizumab, Zimberelimab, Balstilimab, Envafolimab, HLX10, INCB099280, and others. • PD-L1 Inhibitors Therapeutic Assessment: PD-L1 Inhibitors, currently marketed, and PD-L1 Inhibitors emerging therapies • PD-L1 Inhibitors Market Dynamics: PD-L1 Inhibitors market drivers and PD-L1 Inhibitors market barriers • Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies • PD-L1 Inhibitors Unmet Needs, KOL's views, Analyst's views, PD-L1 Inhibitors Market Access and Reimbursement Table of Contents 1. PD-L1 Inhibitors Market Report Introduction 2. Executive Summary for PD-L1 Inhibitors 3. SWOT analysis of PD-L1 Inhibitors 4. PD-L1 Inhibitors Patient Share (%) Overview at a Glance 5. PD-L1 Inhibitors Market Overview at a Glance 6. PD-L1 Inhibitors Disease Background and Overview 7. PD-L1 Inhibitors Epidemiology and Patient Population 8. Country-Specific Patient Population of PD-L1 Inhibitors 9. PD-L1 Inhibitors Current Treatment and Medical Practices 10. PD-L1 Inhibitors Unmet Needs 11. PD-L1 Inhibitors Emerging Therapies 12. PD-L1 Inhibitors Market Outlook 13. Country-Wise PD-L1 Inhibitors Market Analysis (2020–2034) 14. PD-L1 Inhibitors Market Access and Reimbursement of Therapies 15. PD-L1 Inhibitors Market Drivers 16. PD-L1 Inhibitors Market Barriers 17. PD-L1 Inhibitors Appendix 18. PD-L1 Inhibitors Report Methodology 19. DelveInsight Capabilities 20. Disclaimer 21. About DelveInsight About DelveInsight DelveInsight is a leading Healthcare Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefit from market analysis to accelerate business growth and overcome challenges with a practical approach. Media Contact Company Name: DelveInsight Contact Person: Jatin Vimal Email: Send Email Phone: +14699457679 Address: 304 S. Jones Blvd #2432 City: Las Vegas State: Nevada Country: United States Website:

Dermatomyositis Market Set to Advance with Improved Diagnosis and Emerging Immunotherapies by 2034
Dermatomyositis Market Set to Advance with Improved Diagnosis and Emerging Immunotherapies by 2034

Globe and Mail

time2 hours ago

  • Globe and Mail

Dermatomyositis Market Set to Advance with Improved Diagnosis and Emerging Immunotherapies by 2034

Dermatomyositis is a rare, chronic, inflammatory myopathy characterized by progressive muscle weakness and distinctive skin rashes, often associated with autoimmune mechanisms. It can occur in both adults and children and may involve complications such as interstitial lung disease, malignancy, and calcinosis. Despite its rarity, dermatomyositis remains a significant clinical concern due to its multisystem involvement, diagnostic complexity, and limited treatment options. DelveInsight's ' Dermatomyositis Market Insight, Epidemiology, and Market Forecast – 2034 ' provides an in-depth analysis of the current landscape and future outlook of the DM market across major geographies, including the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan. The report explores detailed epidemiological trends, segmentation by age and clinical subtypes, and diagnostic challenges that contribute to underreporting and delayed intervention. Current treatment regimens typically include corticosteroids, immunosuppressants (methotrexate, azathioprine), intravenous immunoglobulin (IVIG), and emerging biologics like rituximab. However, response rates vary, and long-term use can lead to significant side effects. A growing pipeline of investigational agents—targeting pathways such as type I interferons and B-cell modulation—offers promising avenues for disease-specific and steroid-sparing therapies. The Dermatomyositis market is projected to witness steady growth through 2034, fueled by increased disease recognition, clinical trial activity, and strategic advancements by pharmaceutical companies. Biotech firms and academic institutions are exploring novel immunomodulatory agents and precision medicine approaches to improve outcomes in both adult and pediatric populations. DelveInsight's report is an essential resource for pharmaceutical executives, clinical researchers, investors, and healthcare professionals who seek strategic insights into the evolving DM landscape, from market dynamics and unmet needs to the competitive pipeline shaping the future of dermatomyositis care. Some of the Key Facts of the Dermatomyositis Market Report: • In 2023, the dermatomyositis market in the 7MM was valued at approximately USD 187 million, and is projected to grow at a CAGR of 16.8% due to improved disease awareness, diagnostics, and the introduction of new therapies. • The U.S. had the highest number of diagnosed cases, with around 38.5K in 2023. • Across the 7MM, there were nearly 72K diagnosed prevalent cases in 2023, with 91% in adults and 9% in juveniles. • The U.S. accounted for ~54% of total diagnosed cases, while EU4 and the UK represented about 29%, and Japan ~17%. • In January 2025, RESTEM announced that the FDA granted Fast Track designation for its Restem-L program, using umbilical cord outer lining stem cells (ULSCs) to treat Polymyositis and Dermatomyositis (PM/DM), now classified as Idiopathic Inflammatory Myopathy (IIM). This follows the recent Orphan Drug Designation for Restem-L in IIM. • In July 2024, Priovant Therapeutics announced the completion of enrollment for its Phase 3 VALOR trial evaluating brepocitinib in dermatomyositis. With 241 participants across 90 sites on four continents, it is the largest interventional trial ever conducted for the condition. • Leading companies in the Dermatomyositis market include Kezar Life Sciences, Argenx, Pfizer, CSL Behring, Viela Bio, PAEAN Biotechnology, Alexion Pharmaceuticals, and others. • Emerging acute Dermatomyositis drugs include KZR-616, EFG PH20, PF 06823859, Hizentra, Daxdilimab, PN 101, Ravulizumab, and others. • The increasing prevalence of dermatomyositis and ongoing advancements in therapeutic options are driving the demand for more effective treatment approaches. To know in detail about the dermatomyositis market outlook, drug uptake, treatment scenario, and epidemiology trends, click here: Dermatomyositis Market Forecast Dermatomyositis Overview Dermatomyositis is a rare, systemic autoimmune disorder characterized by chronic inflammation of the skin and muscles. It presents with hallmark features such as symmetric proximal muscle weakness and distinctive skin rashes, including the heliotrope rash and Gottron's papules. The condition may also affect other organs, including the lungs, esophagus, and heart, and is sometimes associated with malignancy, especially in adults. Dermatomyositis affects both adults and children (juvenile dermatomyositis), with varying severity. Its exact etiology remains unclear but is believed to involve a combination of genetic predisposition, immune system dysregulation, and environmental triggers. Diagnosis typically involves a combination of clinical findings, elevated muscle enzymes, electromyography (EMG), imaging studies, skin/muscle biopsies, and autoantibody testing. Management of dermatomyositis requires a multidisciplinary approach, involving dermatologists, rheumatologists, neurologists, and physical therapists. While there is no cure, a range of therapies aim to control inflammation, alleviate symptoms, and prevent complications. Get a free sample of the dermatomyositis market report with key insights and emerging therapies here: Dermatomyositis Epidemiology The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2020 to 2034. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends. Dermatomyositis Epidemiology Segmentation: The Dermatomyositis epidemiology chapter in the report provides historical as well as forecasted epidemiology segmented by: • Diagnosed Dermatomyositis prevalence • Type-specific Diagnosed Dermatomyositis prevalence • Age-specific Diagnosed Dermatomyositis prevalence • Gender-specific Diagnosed Prevalent Cases of Dermatomyositis • Severity-specific Diagnosed Prevalent Cases of Dermatomyositis • Chronicity-specific Diagnosed Prevalent Cases of Dermatomyositis Download the report to understand which factors are driving dermatomyositis epidemiology trends @ Dermatomyositis Epidemiology Forecast Dermatomyositis Drugs Uptake and Pipeline Development Activities The Dermatomyositis drugs uptake section examines the rate at which newly launched or upcoming potential drugs are being adopted in the Dermatomyositis market during the study period. This analysis covers drug uptake, patient adoption of therapies, and the sales performance of each drug. Additionally, the therapeutics assessment section highlights the drugs with the most rapid uptake, shedding light on the factors driving their widespread use. It also provides a comparative analysis of these drugs based on their market share. The report further delves into the Dermatomyositis pipeline development activities, offering key insights into various therapeutic candidates in different stages of development and the major companies behind these innovations. It also covers recent collaborations, acquisitions, mergers, licensing agreements, patent details, and other critical information related to emerging therapies. Dermatomyositis Market Outlook While there is no definitive cure for dermatomyositis, available treatments aim to reduce inflammation, control symptoms, and improve quality of life. The approval of OCTAGAM and the development of multiple clinical management guidelines—such as those from the British Society for Rheumatology and the Japanese Society of Rheumatology—have significantly shaped and standardized the therapeutic landscape. Treatment often begins with corticosteroids to manage muscle inflammation, followed by immunosuppressants or immunomodulators like methotrexate, azathioprine, or mycophenolate mofetil to reduce steroid dependency. For resistant or severe cases, advanced therapies such as rituximab, IVIG, and calcineurin inhibitors are employed. In terms of skin manifestations, management includes both topical agents (e.g., corticosteroids, calcineurin inhibitors) and systemic medications like hydroxychloroquine. Adjunctive strategies such as physiotherapy, sun protection, and dietary interventions are also integral. A growing pipeline featuring therapies like Brepocitinib (Priovant/Pfizer), Dazukibart (Pfizer), Efgartigimod (Argenx), and SAPHNELO (AstraZeneca) reflects an evolving research focus on immunomodulation and interferon signaling pathways. These emerging agents, combined with better diagnostics and increasing disease awareness, are expected to drive market growth through 2034. Dermatomyositis Market Strengths • A strong research focus on immune pathways (e.g., JAK-STAT, interferon) has led to promising investigational drugs such as Brepocitinib and Anifrolumab, indicating future therapeutic breakthroughs. • Increasing awareness among clinicians and availability of diagnostic tools (e.g., autoantibody profiling, MRI) enable earlier diagnosis and more tailored treatment strategies. Dermatomyositis Market Weaknesses • Despite multiple treatment options, none offer a cure, and many patients experience relapses or partial responses, necessitating lifelong management. • A significant portion of treatment regimens relies on off-label drug use, which lacks robust clinical trial data, leading to variable efficacy and safety outcomes across patient populations. Scope of the Dermatomyositis Market Report • Study Period: 2020–2034 • Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan] • Key Dermatomyositis Companies: Kezar Life Sciences, Argenx, Pfizer, CSL Behring, Viela Bio, PAEAN Biotechnology, Alexion Pharmaceuticals, and others. • Key Dermatomyositis Therapies: KZR-616, EFG PH20, PF 06823859, Hizentra, Daxdilimab, PN 101, Ravulizumab, and others. • Dermatomyositis Therapeutic Assessment: Dermatomyositis, currently marketed, and Dermatomyositis emerging therapies • Dermatomyositis Market Dynamics: Dermatomyositis market drivers and Dermatomyositis market barriers • Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies • Dermatomyositis Unmet Needs, KOL's views, Analyst's views, Dermatomyositis Market Access and Reimbursement To learn more about the key players and advancements in the dermatomyositis treatment landscape, visit the Dermatomyositis Market Analysis Report Table of Contents 1. Dermatomyositis Market Report Introduction 2. Executive Summary for Dermatomyositis 3. SWOT analysis of Dermatomyositis 4. Dermatomyositis Patient Share (%) Overview at a Glance 5. Dermatomyositis Market Overview at a Glance 6. Dermatomyositis Disease Background and Overview 7. Dermatomyositis Epidemiology and Patient Population 8. Country-Specific Patient Population of Dermatomyositis 9. Dermatomyositis Current Treatment and Medical Practices 10. Dermatomyositis Unmet Needs 11. Dermatomyositis Emerging Therapies 12. Dermatomyositis Market Outlook 13. Country-Wise Dermatomyositis Market Analysis (2020–2034) 14. Dermatomyositis Market Access and Reimbursement of Therapies 15. Dermatomyositis Market Drivers 16. Dermatomyositis Market Barriers 17. Dermatomyositis Appendix 18. Dermatomyositis Report Methodology 19. DelveInsight Capabilities 20. Disclaimer 21. About DelveInsight About DelveInsight DelveInsight is a leading Healthcare Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefit from market analysis to accelerate business growth and overcome challenges with a practical approach. Media Contact Company Name: DelveInsight Contact Person: Jatin Vimal Email: Send Email Phone: +14699457679 Address: 304 S. Jones Blvd #2432 City: Las Vegas State: Nevada Country: United States Website:

Systemic Mastocytosis Clinical Trial Analysis: Key Insights into Rich Pipeline Featuring 8+ Companies and 8+ Therapies
Systemic Mastocytosis Clinical Trial Analysis: Key Insights into Rich Pipeline Featuring 8+ Companies and 8+ Therapies

Globe and Mail

time2 hours ago

  • Globe and Mail

Systemic Mastocytosis Clinical Trial Analysis: Key Insights into Rich Pipeline Featuring 8+ Companies and 8+ Therapies

DelveInsight's, 'Systemic Mastocytosis Pipeline Insight, 2025,' report provides comprehensive insights about 8+ companies and 8+ pipeline drugs in Systemic Mastocytosis pipeline landscape. It covers the Systemic Mastocytosis pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Systemic Mastocytosis pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space. Discover the latest drugs and treatment options in the Systemic Mastocytosis Pipeline. Dive into DelveInsight's comprehensive report today! @ Systemic Mastocytosis Pipeline Outlook Key Takeaways from the Systemic Mastocytosis Pipeline Report In May 2025, M.D. Anderson Cancer Center announced a clinical research study is to see if RAD001 can help to control the disease in patients with systemic mastocytosis (SM). The safety of this treatment will also be studied. RAD001 is designed to stop cancer cells from multiplying. It may also stop the growth of new blood vessels that help tumor growth, which may cause the tumor cells to die. In May 2025, Cogent Biosciences Inc. announced a Phase 2 study investigating CGT9486 for the treatment of patients with Advanced Systemic Mastocytosis (AdvSM), including patients with Aggressive SM (ASM), SM with Associated Hematologic Neoplasm (SM-AHN), and Mast Cell Leukemia (MCL). DelveInsight's Systemic Mastocytosis Pipeline report depicts a robust space with 8+ active players working to develop 8+ pipeline therapies for Systemic Mastocytosis treatment. The leading Systemic Mastocytosis Companies such as AB Sciences, Blueprint Medicines, Patara Pharma, Seagen Inc., GT Biopharma, Deciphera Pharmaceuticals, Novartis Oncology and others. Promising Systemic Mastocytosis Pipeline Therapies such as PA101, Avapritinib, RAD001 (Everolimus), Elenestinib, Masitinib, Avapritinib, Brentuximab vedotin, TL-895 and others. Stay ahead with the most recent pipeline outlook for Systemic Mastocytosis. Get insights into clinical trials, emerging therapies, and leading companies with Systemic Mastocytosis @ Systemic Mastocytosis Treatment Drugs Systemic Mastocytosis Emerging Drugs Profile Avapritinib: Blueprint Medicines Avapritinib is a potent and selective inhibitor of activated KIT and PDGFRA mutant kinases. In certain diseases, mutations in KIT and PDGFRA force protein kinases into an increasingly active state. Avapritinib is uniquely designed to bind and inhibit the active conformation of these proteins. Blueprint Medicines is developing AYVAKIT globally for the treatment of advanced and indolent SM. Blueprint Medicines has an exclusive collaboration and license agreement with CStone Pharmaceuticals for the development and commercialization of AYVAKIT in Mainland China, Hong Kong, Macau and Taiwan. Blueprint Medicines retains development and commercial rights for AYVAKIT in the rest of the world. The FDA granted breakthrough therapy designation to AYVAKIT for the treatment of advanced SM, including the subtypes of aggressive SM, SM with an associated hematological neoplasm and mast cell leukemia, and for the treatment of moderate to severe indolent SM. The FDA has accepted a supplemental new drug application for avapritinib for the treatment of advanced SM. The European Medicines Agency has validated a Type II variation marketing authorization application for avapritinib for the treatment of advanced SM. Masitinib: AB Sciences Masitinib's anti-mast cell properties appear particularly well-adapted to the treatment of indolent systemic mastocytosis. A reduction of mast cell activity is generated via its inhibitory action on wild-type c-Kit, Lyn and Fyn tyrosine kinases. In recognition of the critical need for new treatments, masitinib received orphan drug designation for mastocytosis from both the European Medicine Agency (EMA) and the U.S. Food and Drug Administration (FDA). AB Science initiated a confirmatory phase 3 study, with design optimized based on findings from the first phase 3 study. The Systemic Mastocytosis Pipeline Report Provides Insights into The report provides detailed insights about companies that are developing therapies for the treatment of Systemic Mastocytosis with aggregate therapies developed by each company for the same. It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Systemic Mastocytosis Treatment. Systemic Mastocytosis Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects. Systemic Mastocytosis Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type. Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Systemic Mastocytosis market Explore groundbreaking therapies and clinical trials in the Systemic Mastocytosis Pipeline. Access DelveInsight's detailed report now! @ New Systemic Mastocytosis Drugs Systemic Mastocytosis Companies AB Sciences, Blueprint Medicines, Patara Pharma, Seagen Inc., GT Biopharma, Deciphera Pharmaceuticals, Novartis Oncology and others. Systemic Mastocytosis pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as Oral Parenteral Intravenous Subcutaneous Topical Molecule Type Systemic Mastocytosis Products have been categorized under various Molecule types such as Monoclonal Antibody Peptides Polymer Small molecule Gene therapy Product Type Unveil the future of Systemic Mastocytosis Treatment. Learn about new drugs, Systemic Mastocytosis Pipeline developments, and key companies with DelveInsight's expert analysis @ Systemic Mastocytosis Market Drivers and Barriers Scope of the Systemic Mastocytosis Pipeline Report Coverage- Global Systemic Mastocytosis Companies- AB Sciences, Blueprint Medicines, Patara Pharma, Seagen Inc., GT Biopharma, Deciphera Pharmaceuticals, Novartis Oncology and others. Systemic Mastocytosis Pipeline Therapies- PA101, Avapritinib, RAD001 (Everolimus), Elenestinib, Masitinib, Avapritinib, Brentuximab vedotin, TL-895 and others. Systemic Mastocytosis Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination Systemic Mastocytosis Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III Get the latest on Systemic Mastocytosis Pipeline Therapies and clinical trials. Download DelveInsight's in-depth pipeline report today! @ Systemic Mastocytosis Companies, Key Products and Unmet Needs Table of Content Introduction Executive Summary Systemic Mastocytosis: Overview Pipeline Therapeutics Therapeutic Assessment Systemic Mastocytosis – DelveInsight's Analytical Perspective In-depth Commercial Assessment Systemic Mastocytosis Collaboration Deals Late Stage Products (Preregistration) Avapritinib: Blueprint Medicines Drug profiles in the detailed report….. Mid Stage Products (Phase II) PA101: Patara Pharma Drug profiles in the detailed report….. Early stage products (Phase I) DCC-2618: Deciphera Pharmaceuticals Drug profiles in the detailed report….. Inactive Products Systemic Mastocytosis Key Companies Systemic Mastocytosis Key Products Systemic Mastocytosis- Unmet Needs Systemic Mastocytosis- Market Drivers and Barriers Systemic Mastocytosis- Future Perspectives and Conclusion Systemic Mastocytosis Analyst Views Systemic Mastocytosis Key Companies Appendix About Us DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve Media Contact Company Name: DelveInsight Business Research LLP Contact Person: Yash Bhardwaj Email: Send Email Phone: 09650213330 Address: 304 S. Jones Blvd #2432 City: Las Vegas State: NV Country: United States Website:

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into the world of global news and events? Download our app today from your preferred app store and start exploring.
app-storeplay-store